Fomivirsen

Drugs

Volumn 57, Issue 3, 1999, Pages 375-380

  Perry, Caroline M ^a   Balfour, Julia A Barman ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOMIVIRSEN; GANCICLOVIR; MESSENGER RNA; STEROID; VIRUS RNA; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG BINDING; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; EYE TOXICITY; HUMAN; HUMAN CYTOMEGALOVIRUS; INFLAMMATION; INTRAOCULAR HYPERTENSION; INTRAVITREAL DRUG ADMINISTRATION; MONKEY; NONHUMAN; RETINA; RETINITIS; RNA TRANSCRIPTION; VIRUS REPLICATION;

EID: 0033022872     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957030-00010     Document Type: Article

References (21)

1. Nokta MA, Hausrath SG, Pollard RB. Emerging treatments for viral retinitis. Biodrugs 1997 Jun; 7: 423-32
2. Temsamani J, Pari GS, Guinot P. Antisense approach for the treatment of cytomegalovirus infection. Expert Opin Invest Drug 1997 Sep; 6: 1157-67
3. Bonn D. Prospects for antisense therapy are looking brighter [news]. Lancet 1996 Mar 23; 347: 820
4. Fraser GL, Wahlestedt C. Applications of antisense technology to both basic and clinical research. Expert Opin Invest Drug 1995; 4 (7): 637-46
5. Azad RF, Driver VB, Tanaka K. Antiviral activity of a phosphorothioate oligonucleotide complementary to RNA of the human cytomegalovirus major immediate-early region. Antimicrob Agents Chemother 1993 Sep; 37: 1945-54
6. Anderson KP, Fox MC, Brown-Driver V, et al. Inhibition of human cytomegalovirus immediate-early gene expression by an antisense oligonucleotide complementary to immediate-early RNA. Antimicrob Agents Chemother 1996 Sep; 40: 2004-11
7. Henahan S. Fomivirsen focuses on the future in CMV retinitis. Inpharma 1998 May 23; 1138: 11
8. Azad RF, Brown-Driver V, Buckheit JRW, et al. Antiviral activity of a phosphorothinate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res 1995 Oct; 28: 101-11
9. Mulamba GB, Hu A, Azad RF, et al. Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922). Antimicrob Agents Chemother 1998 Apr; 42: 971-3
10. Leeds JM, Henry SP, Truong L, et al. Pharmacokinetics of a potential human cytomegalovirus therapeutic, a phosphorothinate oligonucleotide, after intravitreal injection in the rabbit. Drug Metab Dispos 1997 Aug; 25: 921-6
11. Leeds JM, Henry SP, Bistner S, et al. Pharmacokinetics of an antisense oligonucleotide injected intravitreally in monkeys. Drug Metab Dispos 1998 Jul; 26: 670-5
12. Johnson DW, Muccioli C, Goldstein DA, et al. Safety and efficacy of fomivirsen in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract]. 8th International Congress on Infectious Diseases; 1998 May 15-18; Boston, 135
13. Muccioli C, Goldstein DA, Johnson DW, et al. Fomivirsen safety and efficacy in the treatment of CMV retinitis: a phase 3, controlled, multicenter study comparing immediate versus delayed treatment [abstract]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb; Chicago, 224
14. Isis Pharmaceuticals, Carlsbad, California. 1998 (Data on file)
15. Hutcherson SL, Palestine AG, Cantrill HL, et al. Antisense oligonucleotide safety and efficacy for CMV retinitis in AIDS patients [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17; San Francisco, 204
16. Isis Vitravene may be considered for first-line use in CMV retinitis. The Pink Sheet 1998 Jul 27: 5
17. ISIS and CIBA vision present positive phase III results for antisense CMV retinitis drug advanced disease trial results support earlier findings; NDA submission imminent. Newswire; http:/wwwnewspagecom 1998
18. FDA panel supports Isis's antisense drug. Scrip Mag 1998 Jul 29 (2356): 22
19. Hudson HL, Boyer DS, Kupperman BD. Future trends and experimental modalities in the therapeutics of cytomegalovirus retinitis. Ophthal Clin North Am 1997; 10(1): 61-71
20. Isis/Ciba Antisense Compound Vitravene approved for CMV retinitis. The Pink Sheet 1998 Aug 31: 27
21. Isis Pharmaceuticals USA. Fomivirsen sodium prescribing information. 1998